Antibody building blocks stuck together with bacterial superglue can protect against bunyaviruses, and herald a new approach to developing antibodies to fight emerging viruses.
Synthetic antibodies constructed using bacterial superglue can neutralise potentially lethal viruses, according to a study published last week in eLife.
The findings provide a new approach to preventing and treating infections of emerging viruses and could also potentially be used in therapeutics for other diseases.
Bunyaviruses are mainly carried by insects, such as mosquitoes, and can have devastating effects on animal and human health. The World Health Organization has included several of these viruses on the Blueprint list of pathogens likely to cause epidemics in humans in the face of absent or insufficient countermeasures.
“After vaccines, antiviral and antibody therapies are considered the most effective tools to fight emerging life-threatening virus infections,” explains author Paul Wichgers Schreur, a senior scientist of Wageningen Bioveterinary Research, The Netherlands. “Specific antibodies called VHHs have shown great promise in neutralising a respiratory virus of infants. We investigated if the same antibodies could be effective against emerging bunyaviruses.”
Antibodies naturally found in humans and most other animals are composed of four ‘chains’ – two heavy and two light. VHHs are the antigen-binding domains of heavy chain-only antibodies found in camelids and are fully functional as a single domain. This makes VHHs smaller and able to bind to pathogens in ways that human antibodies cannot. Furthermore, the single chain nature makes them perfect building blocks for the construction of multifunctional complexes.
In this study, the researchers immunised llamas with two prototypes of bunyaviruses, the Rift Valley fever virus (RVFV) and the Schmallenberg virus (SBV), to generate VHHs that target an important part of the virus’ infective machinery, the glycoprotein head. They found that RVFV and SBV VHHs recognised different regions within the glycoprotein structure.
When they tested whether the VHHs could neutralise the virus in a test tube, they found that single VHHs could not do the job. Combining two different VHHs had a slightly better neutralising effect against SBV, but this was not effective for RVFV. To address this, the team used ‘superglue’ derived from bacteria to stick multiple VHHs together as a single antibody complex. The resulting VHH antibody complexes efficiently neutralised both viruses, but only if the VHHs in the complex targeted more than one region of the virus glycoprotein head.
Studies in mice with the best performing VHH antibody complexes showed that these complexes were able to prevent death. The number of viruses in the blood of the treated mice was also substantially reduced compared with the untreated animals.
To work in humans optimally, antibodies need to have all the effector functions of natural human antibodies. To this end, the team constructed llama-human chimeric antibodies. Administering a promising chimeric antibody to mice before infection prevented lethal disease in 80% of the animals, and treating them with the antibody after infection prevented mortality in 60%.
“We’ve harnessed the beneficial characteristics of VHHs in combination with bacterial superglues to develop highly potent virus neutralising complexes,” concludes senior author Jeroen Kortekaas, Senior Scientist at Wageningen Bioveterinary Research, and Professor of the Laboratory of Virology, Wageningen University, The Netherlands. “Our approach could aid the development of therapeutics for bunyaviruses and other viral infections, as well as diseases including cancer.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Pfizer and Moderna vaccines produce robust immune responses in pregnant and nursing womenon May 13, 2021 at 8:23 am
The results of the Beth Israel study are similar to those in another study published in March in the American Journal of Obstetrics and Gynecology by researchers from Massachusetts General Hospital ...
- What is an Antibody Library?on May 13, 2021 at 4:12 am
There are four types of combinatorial antibody libraries. These are immune, naïve, semi-synthetic, and synthetic libraries. Immune libraries use antibodies from immunized humans or animals ...
- A 'Universal Vaccine' May Soon Protect Against All Coronaviruses, Including the Common Coldon May 12, 2021 at 2:00 am
Even as scientists race to develop booster shots and tweak existing vaccines to work against new variants to SARS2, they're looking ahead to future pandemics caused by entirely new pathogens from the ...
- CellectSeq: In silico discovery of antibodies targeting integral membrane proteins combining in situ selections and next-generation sequencingon May 11, 2021 at 5:00 pm
Kelil, Gallo et al. develop an antibody discovery strategy, termed CellectSeq, for targeting integral membrane proteins on native cells. This strategy uses motif-based scoring and sequencing ...
- Reawakened immune cells show promise in mice against zombie cells tied to diseases of agingon May 10, 2021 at 3:55 pm
Rather than needing to be genetically engineered or primed with synthetic antibodies, they just need to be turned on. In mice, researchers reported on Monday in the journal Med, activating NKT ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Virus neutralising complexes
- Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Goodon May 17, 2021 at 4:01 am
COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 / In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) ( and Intel Corporation ( has published a thought leadership collaboration. The white ...
- Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use ...on May 17, 2021 at 4:00 am
COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 /In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) ( and Intel Corporation ( has published a thought leadership collaboration. The white ...
- COVID-19 response over next 6-18 months critical, says Soumya Swaminathanon May 16, 2021 at 8:53 pm
Predicting that the COVID-19 pandemic is likely to have subsequent waves as well, Dr. Soumya Swaminathan, chief scientist at the World Health Organization, who has been maintaining a keen eye on the ...
- Preventing respiratory syncytial virus (RSV) disease in childrenon May 14, 2021 at 12:31 am
In 1957, a virus recovered from infants with lower respiratory tract illness (LRTI) was named respiratory syncytial virus (RSV) for its ability to form multinucleated cells (syncytia) in cell culture ...
- A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunityon May 13, 2021 at 8:56 pm
In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 ...